Pentraxin-3 a novel biomarker for predicting coronary artery disease

Abstract

Aim: Atherosclerotic cardiovascular disease (CVD) is a chronic progressing disorder leading to the most common cause of death. Risk estimation helps health professionals to find who will take the advantage most. Pentraxin-3 (PTX-) is a member of pentraxin family which is more spesific to vascular inflammation than hs-CRP, another member of pentraxin family. In this study, we aimed to find the relationship between serum PTX-3 and hs-CRP levels and the presence of atherosclerotic heart disease. Methods: Between December 2010 and June 2011, 88 patients with stable angina pectoris referred to catheter lab were enrolled. Patients were divided into 2 groups according to the presence of angiographic coronary disease (ACD). Group 1 consisted of patients without ACD (N:33), group 2 consisted of patients with ACD (N:54) Serum PTX-3 and hs-CRP levels were obtained prior to catheterization. Results: Baseline characteristics are given at Table 1. PTX-3 levels in group 2 were significantly higher than group 1 (median 2,50 vs 1,20 ng/mL, p <0,001). However hs-CRP levels were non-significant between 2 groups (p=0,065). On multivariate analyses, PTX-3 levels (OR: 1,6 p=0,015) and male gender (OR:0,34 p=0,032) were found to be independent predictors for ACD. Cut-off value for PTX-3 level to show the presence of ACD was found to be 1,52 ng/mL (specificity %69,7, sensitivity %79,6). View this table: Table 1 Conclusion: Pentraxin 3, a novel inflammatory biomarker, is a better predictor for the presence of ACD than hs-CRP and can add more valuable information for primary prevention risk estimation.